Open to all scientists researching new therapeutics in Cambridge and the local area

The purpose of the CamNTF forum is to promote interactions between scientists from academia & industry in order to improve opportunities for biotechnology research and development. Meeting attendance is free but all attendees must register in advance.

CamNTF was founded in 2015 by Dr David Rees (Astex Pharmaceuticals, CSO) in collaboration with Professor Sir Tom Blundell (University of Cambridge, Sir William Dunn Professor of Biochemistry) and Professor Patrick Maxwell (University of Cambridge, Regius Professor of Physic, Director Cambridge University Health Partners).

The forum was made possible by key scientific sponsors: Professor Michael Wakelam (Babraham Institute, Director), Professor Ewan Birney (EMBL-EBI, Associate Director), Dr Mene Pangalos (AstraZeneca, R&D Director) and Professor Ian Wilkinson (University of Cambridge, Professor of Therapeutics; Director of CUHP’s Office for Translational Research).

The next meeting will be on:
data-driven approaches to understand disease mechanisms and systematically identify and prioritise drug targets.

Thursday 2 July 2026 (16:30 – 19:00)

EMBL-EBI South Building, Wellcome Genome Campus, Hinxton, CB10 1SD

REGISTER (FREE) TO THE EVENT FOLLOWING THE LINK BELOW.

https://www.eventbrite.co.uk/e/cambridge-new-therapeutics-forum-july-2026-meeting-tickets-1989987791052

 

Six meeting a year are organised, around Cambridge, hosted by various organisations and covering a wide range of topics all related to new therapeutics.